SCHEMBL321051

SCHEMBL321051

CCOC(=O)c1cn(C)c2ccc(C(=O)c3c(C)c(OC)c4ccccn34)cc2c1=O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.44
▸ KDM4E B2RXH2 2/20 0.44
▸ HPGD P15428 2/20 0.44
▸ GLA P06280 1/20 0.44
▸ GAA P10253 1/20 0.44
▸ NPSR1 Q6W5P4 1/20 0.42
▸ RXFP1 Q9HBX9 1/20 0.42
▸ FNTA P49354 1/20 0.41
▸ FNTB P49356 1/20 0.41
▸ LMNA P02545 3/20 0.41
▸ MAOB P27338 1/20 0.40
▸ MAPT P10636 4/20 0.39
▸ TP53 P04637 4/20 0.38
▸ SMN1; SMN2 Q16637 3/20 0.38
▸ NR4A2 P43354 1/20 0.36
▸ POLB P06746 1/20 0.36
▸ MEN1 O00255 1/20 0.36
▸ RECQL P46063 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ CNR1 P21554 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL320775 0.89 POLB (0.41) ALDH1A1KDM4EHPGDLMNAMAPT
SCHEMBL17004134 0.84 HTT (0.39) ALDH1A1KDM4EGAARXFP1LMNA
SCHEMBL321292 0.83 ALDH1A1 (0.52) ALDH1A1KDM4EHPGDGLAGAA
SCHEMBL320313 0.83 L3MBTL1 (0.48) ALDH1A1KDM4EHPGDGLAGAA
SCHEMBL321028 0.78 HCRTR1 (0.44) ALDH1A1KDM4EHPGDGLAGAA
SCHEMBL320650 0.76 HTT (0.38) ALDH1A1KDM4EGAARXFP1LMNA
SCHEMBL321038 0.74 KDM4E (0.42) ALDH1A1KDM4EHPGDGAANPSR1
SCHEMBL321215 0.74 NR4A2 (0.43) ALDH1A1KDM4EHPGDNPSR1LMNA
SCHEMBL15071685 0.74 ALDH1A1 (0.57) ALDH1A1KDM4EHPGDGLAGAA
SCHEMBL10084828 0.73 LMNA (0.58) ALDH1A1KDM4EHPGDGAANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2590975-B1 INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI SA (FR) 2015-08-19 — — EP disclosed
US-8859544-B2 Indolizine derivatives, process for the preparation thereof and therapeutic use thereof SANOFI (FR) 2014-10-14 — — US disclosed
EP-2590975-A1 INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2013-05-15 — — EP disclosed
US-20130116249-A1 INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2013-05-09 — — US disclosed
WO-2012004731-A1 INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2012-01-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130116249-A1 INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF CCNY, INMT, IDO1 ALDH1A1 3536/4885KDM4E 633/4885HPGD 810/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback